Top

Clinical and Translational Oncology

Published in:

01-08-2017 | Research Article

SOX10 is over-expressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors

Authors: H. Yin, C. Qin, Y. Zhao, Y. Du, Z. Sheng, Q. Wang, Q. Song, L. Chen, C. Liu, T. Xu

Published in: Clinical and Translational Oncology | Issue 8/2017

Abstract

Purpose

To detect the expression level and significance of SOX10 in human bladder cancer.

Methods

Immunohistochemical analyses were performed to assess SOX10 protein level using a bladder cancer tissue microarray (including 59 spots of cancer tissues and 46 spots of paired normal tissues) and 31 specimens and to define the relationship between SOX10 and clinicopathological bladder cancer characteristics in patients. SOX10 protein and mRNA levels in bladder cancer cell lines (T24, 5637, BIU87, EJ) and transitional cell papilloma cell line (RT4) were tested by western blotting and quantitative real-time PCR (q-PCR), respectively. Cell Counting Kit-8 (CCK-8) and colony formation assays were performed to investigate bladder cancer cell proliferation after SOX10 knockdown. The effect of SOX10 on cell migration and invasion was analyzed by Transwell and Matrigel assays. Kaplan–Meier survival curves and Cox regression analyses were used to evaluate SOX10 prognostic significance for bladder cancer patients. The mechanisms by which SOX10 promote bladder cancer progression were examined by western blotting.

Results

SOX10 protein was upregulated in 74.4% of bladder cancer tissues compared with adjacent normal tissues (32.6%). SOX10 protein was also upregulated in malignant cell lines. In addition, high SOX10 expression was related with clinical stage (P = 0.008), T stage (P = 0.004), histological grade (P = 0.002) and lymph node metastasis (P = 0.006). Kaplan–Meier survival curves and Cox regression analyses showed that SOX10 functioned as an independent prognostic factor for overall survival. SOX10 knockdown in bladder cancer cells significantly impacted proliferation, migration and invasion, and SOX10 might promote bladder cancer progression by altering β-catenin and Met expression.

Conclusion

SOX10 was over-expressed in bladder cancer and promoted malignant bladder cancer cell behaviors. SOX10 has potential as a molecular target for bladder cancer treatment.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.PubMedCrossRef

Apolo AB, Vogelzang NJ, Theodorescu D. New and promising strategies in the management of bladder cancer. Am Soc Clin Oncol. 2015;35:105–12.CrossRef

Wyszynski A, Tanyos SA, Rees JR, Marsit CJ, Kelsey KT, Schned AR, et al. Body mass and smoking are modifiable risk factors for recurrent bladder cancer. Cancer. 2014;120(3):408–14.PubMedCrossRef

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.PubMedCrossRef

Hennings H, Glick AB, Greenhalgh DA, Morgan DL, Strickland JE, Tennenbaum T, et al. Critical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesis. Proc Soc Exp Biol Med. 1993;202(1):1–8.PubMedCrossRef

Ramos JR, Pabijan J, Garcia R, Lekka M. The softening of human bladder cancer cells happens at an early stage of the malignancy process. Beilstein J Nanotechnol. 2014;5:447–57.PubMedPubMedCentralCrossRef

Gubbay J, Collignon J, Koopman P, Capel B, Economou A, Munsterberg A, et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature. 1990;346(6281):245–50.PubMedCrossRef

Watanabe Y, Broders-Bondon F, Baral V, Paul-Gilloteaux P, Pingault V, et al. Sox10 and Itgb1 interaction in enteric neural crest cell migration. Dev Biol. 2013;379(1):92–106.PubMedCrossRef

Miyahara K, Kato Y, Koga H, Dizon R, Lane GJ, Suzuki R, et al. Visualization of enteric neural crest cell migration in SOX10 transgenic mouse gut using time-lapse fluorescence imaging. J Pediatr Surg. 2011;46(12):2305–8.PubMedCrossRef

10.

Mollaaghababa R, Pavan WJ. The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia. Oncogene. 2003;22(20):3024–34.PubMedCrossRef

11.

Inoue K, Tanabe Y, Lupski JR. Myelin deficiencies in both the central and the peripheral nervous systems associated with a SOX10 mutation. Ann Neurol. 1999;46(3):313–8.PubMedCrossRef

12.

Izumi Y, Musha I, Suzuki E, Iso M, Jinno T, Horikawa R, et al. Hypogonadotropic hypogonadism in a female patient previously diagnosed as having waardenburg syndrome due to a sox10 mutation. Endocrine. 2015;49(2):553–6.PubMedCrossRef

13.

Okamura K, Oiso N, Tamiya G, Makino S, Tsujioka D, Abe Y, et al. Waardenburg syndrome type IIE in a Japanese patient caused by a novel missense mutation in the SOX10 gene. J Dermatol. 2015;42(12):1211–2.PubMedCrossRef

14.

Wenzhi H, Ruijin W, Jieliang L, Xiaoyan M, Haibo L, Xiaoman W, et al. Heterozygous deletion at the SOX10 gene locus in two patients from a Chinese family with Waardenburg syndrome type II. Int J Pediatr Otorhinolaryngol. 2015;79(10):1718–21.PubMedCrossRef

15.

Panaccione A, Chang MT, Carbone BE, Guo Y, Moskaluk CA, Virk RK, et al. NOTCH1 and SOX10 are essential for proliferation and radiation resistance of cancer stem-like cells in adenoid cystic carcinoma. Clin Cancer Res. 2016;22(8):2083–95.PubMedPubMedCentralCrossRef

16.

Kwon AY, Heo I, Lee HJ, Kim G, Kang H, Heo JH, et al. Sox10 expression in ovarian epithelial tumors is associated with poor overall survival. Virchows Arch. 2016;468(5):597–605.PubMedCrossRef

17.

Schmitt AC, Cohen C, Siddiqui MT. Expression of SOX10 in salivary gland oncocytic neoplasms: a review and a comparative analysis with other immunohistochemical markers. Acta Cytol. 2015;59(5):384–90.PubMedCrossRef

18.

Lopez-Anido C, Sun G, Koenning M, Srinivasan R, Hung HA, Emery B, et al. Differential Sox10 genomic occupancy in myelinating glia. Glia., 2015;63(11):1897–914.CrossRef

19.

Zhou D, Bai F, Zhang X, Hu M, Zhao G, Zhao Z, et al. SOX10 is a novel oncogene in hepatocellular carcinoma through Wnt/beta-catenin/TCF4 cascade. Tumour Biol. 2014;35(10):9935–40.PubMedCrossRef

20.

Tong X, Li L, Li X, Heng L, Xhong L, Su X, et al. SOX10, a novel HMG-box-containing tumor suppressor, inhibits growth and metastasis of digestive cancers by suppressing the Wnt/beta-catenin pathway. Oncotarget. 2014;5(21):10571–83.PubMedPubMedCentralCrossRef

21.

Han B, Luan L, Xu Z, Wu B. Clinical significance and biological roles of CRKL in human bladder carcinoma. Tumour Biol. 2014;35(5):4101–6.PubMedCrossRef

22.

Sutherland JM, Sobinoff AP, Fraser BA, Redgrove KA, Davidson TL, Siddall NA, et al. RNA binding protein Musashi-1 directly targets Msi2 and Erh during early testis germ cell development and interacts with IPO5 upon translocation to the nucleus. FASEB J. 2015;29(7):2759–68.PubMedCrossRef

23.

Bondurand N, Kobetz A, Pingault V, Lemort N, Encha-razavi F, Couly G, et al. Expression of the SOX10 gene during human development. FEBS Lett. 1998;432(3):168–72.PubMedCrossRef

24.

Lee KE, Nam S, Cho EA, Seong I, Lima JK, Lee S, et al. Identification of direct regulatory targets of the transcription factor Sox10 based on function and conservation. BMC Genom. 2008;9:408.CrossRef

25.

Bondurand N, Kuhlbrodt K, Pingault V, Enderich J, Sajus M, Tommerup N, et al. A molecular analysis of the yemenite deaf-blind hypopigmentation syndrome: SOX10 dysfunction causes different neurocristopathies. Hum Mol Genet. 1999;8(9):1785–9.PubMedCrossRef

26.

Potterf SB, Furumura M, Dunn KJ, Arnheiter H, Pavan WJ. Transcription factor hierarchy in Waardenburg syndrome: regulation of MITF expression by SOX10 and PAX3. Hum Genet. 2000;107(1):1–6.PubMedCrossRef

27.

Sham MH, Lui VC, Fu M, Chen B, Tam PK. SOX10 is abnormally expressed in aganglionic bowel of Hirschsprung’s disease infants. Gut. 2001;49(2):220–6.PubMedPubMedCentralCrossRef

28.

Bondurand N, Girard M, Pingault V, Lemort N, Dubourg O, Goossens M. Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10. Hum Mol Genet. 2001;10(24):2783–95.PubMedCrossRef

29.

Pingault V, Girard M, Bondurand N, Dorkins H, Van Maldergem L, Mowat D, et al. SOX10 mutations in chronic intestinal pseudo-obstruction suggest a complex physiopathological mechanism. Hum Genet. 2002;111(2):198–206.PubMedCrossRef

30.

Paratore C, Eichenberger C, Suter U, Sommer L. Sox10 haploinsufficiency affects maintenance of progenitor cells in a mouse model of Hirschsprung disease. Hum Mol Genet. 2002;11(24):3075–85.PubMedCrossRef

31.

McKeown SJ, Lee VM, Bronner-Fraser M, Newgreen DF, Farlie PG. Sox10 overexpression induces neural crest-like cells from all dorsoventral levels of the neural tube but inhibits differentiation. Dev Dyn. 2005;233(2):430–44.PubMedCrossRef

32.

Bannykh SI, Stolt CC, Kim J, Perry A, Wegner M. Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. J Neurooncol. 2006;76(2):115–27.PubMedCrossRef

33.

Addo-Yobo SO, Straessle J, Anwar A, Donson AM, Kleinschmidt-demasters BK, Foreman NK. Paired overexpression of ErbB3 and Sox10 in pilocytic astrocytoma. J Neuropathol Exp Neurol. 2006;65(8):769–75.PubMedCrossRef

34.

Yokoyama S, Takeda K, Shibahara S. Functional difference of the SOX10 mutant proteins responsible for the phenotypic variability in auditory-pigmentary disorders. J Biochem. 2006;140(4):491–9.PubMedCrossRef

35.

Ferletta M, Uhrbom L, Olofsson T, Ponten F, Westermark B. Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B–induced gliomagenesis. Mol Cancer Res. 2007;5(9):891–7.PubMedCrossRef

36.

Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008;32(9):1291–8.PubMedCrossRef

37.

Flammiger A, Besch R, Cook AL, Maier T, Sturm RA, Berking C. SOX9 and SOX10 but not BRN2 are required for nestin expression in human melanoma cells. J Invest Dermatol. 2009;129(4):945–53.PubMedCrossRef

38.

Blochin E, Nonaka D. Diagnostic value of Sox10 immunohistochemical staining for the detection of metastatic melanoma in sentinel lymph nodes. Histopathology. 2009;55(5):626–8.PubMedCrossRef

39.

Zhao Y, Liu ZG, Tang J, Zou RF, Chen XY, Jiang GM, et al. High expression of Sox10 correlates with tumor aggressiveness and poor prognosis in human nasopharyngeal carcinoma. Onco Targets Ther. 2016;9:1671–7.PubMedPubMedCentralCrossRef

40.

Mohamed A, Gonzalez RS, Lawson D, Wang J, Cohen C. SOX10 expression in malignant melanoma, carcinoma, and normal tissues. Appl Immunohistochem Mol Morphol. 2013;21(6):506–10.PubMedCrossRef

41.

Ohtomo R, Mori T, Shibata S, Tsuta K, Maeshima AM, Akazawa C, et al. SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis. Mod Pathol. 2013;26(8):1041–50.PubMedCrossRef

42.

Shakhova O, Zingg D, Schaefer SM, Hari L, Civenni G, Blunschi J, et al. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol. 2012;14(8):882–90.PubMedCrossRef

43.

Ponder BA. Cancer genetics. Nature. 2001;411(6835):336–41.PubMedCrossRef

44.

Bartek J. DNA damage response, genetic instability and cancer: from mechanistic insights to personalized treatment. Mol Oncol. 2011;5(4):303–7.PubMedPubMedCentralCrossRef

45.

Groner AC, Cato L, de Tribolet-Hardy J, Bernasocchi T, Janouskova H, Melchers D, et al. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell. 2016;29(6):846–58.PubMedPubMedCentralCrossRef

Title: SOX10 is over-expressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors
Authors: H. Yin
C. Qin
Y. Zhao
Y. Du
Z. Sheng
Q. Wang
Q. Song
L. Chen
C. Liu
T. Xu
Publication date: 01-08-2017
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 8/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1641-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2017

Fecal incontinence and radiation dose on anal sphincter in patients with locally advanced rectal cancer (LARC) treated with preoperative chemoradiotherapy: a retrospective, single-institutional study

MicroRNAs as prognostic biomarker and relapse indicator in leukemia

Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis

BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines

Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas

The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer